Home > Ulka Vaishampayan, ESMO 2020 – ALKS 4230 Monotherapy and Data From the ARTISTRY-1 Trial

Ulka Vaishampayan, ESMO 2020 – ALKS 4230 Monotherapy and Data From the ARTISTRY-1 Trial

Published Online: October 7th 2020
Authors: Ulka Vaishampayan

Dr Ulka Vaishampayan discusses how interleukin-2 may be used as a treatment for solid tumours and the potential role of the ALKS 4230 fusion protein due to its efficacy and safety profile. Data from the ARTISTRY-1 study was presented in the abstract ‘ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)‘ at the Virtual 2020 ESMO Congress, 19–21 September 2020.


  1. What is the mechanism of action of ALKS 4230, and what is the rationale behind targeting interleukin-2 (IL-2) to treat solid tumours? (0:26)
  2. What are the aims and design of the ARTISTRY-1 study? (2:52)
  3. What have been the key interim findings to date? (3:50)
  4. Have there been any safety concerns, and how can these toxicities be managed? (7:03)
  5. What are the future directions for ALKS 4230 and the ARTISTRY-1 trial? (8:09)

Speaker Disclosure: Ulka Vaishampayan has nothing to disclose in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. The ARTISTRY-1 study was sponsored by Alkermes, Inc.

Filmed in coverage of the Virtual 2020 ESMO Congress.

Share this Video
Related Videos In Immunotherapy
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar